45 related articles for article (PubMed ID: 15905566)
1. Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor.
Kalinichenko TV; Mokyr MB
Cancer Immunol Immunother; 1998 Aug; 46(6):293-303. PubMed ID: 9756413
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
3. Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors.
Donepudi M; Quach DD; Mokyr MB
Cancer Immunol Immunother; 1999; 48(2-3):153-64. PubMed ID: 10414470
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
Hörig H; Lee DS; Conkright W; Divito J; Hasson H; LaMare M; Rivera A; Park D; Tine J; Guito K; Tsang KW; Schlom J; Kaufman HL
Cancer Immunol Immunother; 2000 Nov; 49(9):504-14. PubMed ID: 11092617
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
[TBL] [Abstract][Full Text] [Related]
6. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Hance KW; Rogers CJ; Zaharoff DA; Canter D; Schlom J; Greiner JW
Clin Cancer Res; 2009 Apr; 15(7):2387-96. PubMed ID: 19276249
[TBL] [Abstract][Full Text] [Related]
7. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.
Tang YC; Thoman M; Linton PJ; Deisseroth A
Cancer Immunol Immunother; 2009 Dec; 58(12):1949-57. PubMed ID: 19444444
[TBL] [Abstract][Full Text] [Related]
8. Virosome: An engineered virus for vaccine delivery.
Ali H; Akbar M; Iqbal B; Ali F; Sharma NK; Kumar N; Najmi A; Albratty M; Alhazmi HA; Madkhali OA; Zoghebi K; Alam MS
Saudi Pharm J; 2023 May; 31(5):752-764. PubMed ID: 37181145
[No Abstract] [Full Text] [Related]
9. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.
Chesson CB; Zloza A
Nanomedicine (Lond); 2017 Dec; 12(23):2693-2706. PubMed ID: 29098928
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate induces oxidative phosphorylation by activating cytochrome c oxidase in human cultured neurons and astrocytes.
Castellano-González G; Pichaud N; Ballard JW; Bessede A; Marcal H; Guillemin GJ
Oncotarget; 2016 Feb; 7(7):7426-40. PubMed ID: 26760769
[TBL] [Abstract][Full Text] [Related]
11. Virosome presents multimodel cancer therapy without viral replication.
Saga K; Kaneda Y
Biomed Res Int; 2013; 2013():764706. PubMed ID: 24369016
[TBL] [Abstract][Full Text] [Related]
12. Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.
Loisel-Meyer S; Felizardo T; Mariotti J; Mossoba ME; Foley JE; Kammerer R; Mizue N; Keefe R; McCart JA; Zimmermann W; Dropulic B; Fowler DH; Medin JA
Mol Cancer Ther; 2009 Mar; 8(3):692-702. PubMed ID: 19276164
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particles-universal molecular toolboxes.
Ludwig C; Wagner R
Curr Opin Biotechnol; 2007 Dec; 18(6):537-45. PubMed ID: 18083549
[TBL] [Abstract][Full Text] [Related]
14. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine.
Cusi MG; Del Vecchio MT; Terrosi C; Savellini GG; Di Genova G; La Placa M; Fallarino F; Moser C; Cardone C; Giorgi G; Francini G; Correale P
J Immunol; 2005 Jun; 174(11):7210-6. PubMed ID: 15905566
[TBL] [Abstract][Full Text] [Related]
15. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.
Xiang R; Primus FJ; Ruehlmann JM; Niethammer AG; Silletti S; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
J Immunol; 2001 Oct; 167(8):4560-5. PubMed ID: 11591784
[TBL] [Abstract][Full Text] [Related]
16. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.
Santra S; Barouch DH; Jackson SS; Kuroda MJ; Schmitz JE; Lifton MA; Sharpe AH; Letvin NL
J Immunol; 2000 Dec; 165(12):6791-5. PubMed ID: 11120800
[TBL] [Abstract][Full Text] [Related]
17. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems.
Glück R; Metcalfe IC
Vaccine; 2003 Jan; 21(7-8):611-5. PubMed ID: 12531327
[TBL] [Abstract][Full Text] [Related]
19. Costimulatory molecules in vaccine design.
Hodge JW; Schlom J
Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
